Peer Review reports
From: A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models
| Original Submission | ||
|---|---|---|
| 31 Oct 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 10 Jan 2023 | Reviewed | Reviewer Report |
| 13 Feb 2023 | Reviewed | Reviewer Report |
| 18 Mar 2023 | Author responded | Author comments - Yi Zhang |
| Resubmission - Version 3 | ||
| 18 Mar 2023 | Submitted | Manuscript version 3 |
| 28 Mar 2023 | Author responded | Author comments - Yi Zhang |
| Resubmission - Version 4 | ||
| 28 Mar 2023 | Submitted | Manuscript version 4 |
| 6 Apr 2023 | Author responded | Author comments - Yi Zhang |
| Resubmission - Version 5 | ||
| 6 Apr 2023 | Submitted | Manuscript version 5 |
| 12 Apr 2023 | Author responded | Author comments - Yi Zhang |
| Resubmission - Version 6 | ||
| 12 Apr 2023 | Submitted | Manuscript version 6 |
| Publishing | ||
| 24 Apr 2023 | Editorially accepted | |
| 2 Jun 2023 | Article published | 10.1186/s12885-023-10878-3 |
You can find further information about peer review here.